| 依那西普治疗强直性脊柱炎的随机、双盲、平行对照临床研究 |
| |
| 引用本文： | 邓小虎,黄烽,张亚美,杨春花,郭军华,梁东风,李胜光,王莉莎,张江林.依那西普治疗强直性脊柱炎的随机、双盲、平行对照临床研究[J].军医进修学院学报,2009,30(1):21-23. |
| |
| 作者姓名： | 邓小虎 黄烽 张亚美 杨春花 郭军华 梁东风 李胜光 王莉莎 张江林 |
| |
| 作者单位： | 解放军总医院风湿科,北京,100853 |
| |
| 摘 要： | 目的：评价依那西普治疗活动性强直性脊柱炎（AS）的临床疗效和安全性。方法：前6周为随机、双盲、安慰剂对照临床试验，后6周为开放研究。52位活动性AS患者随机接受6周的每周2次依那西普（25mg）或安慰剂皮下注射，主要疗效指标为达到ASAS20的患者比例，次要疗效指标达到ASASS0、ASAS70受试者比例，BAS—DAI改善达到50％的受试者比例。结果：6周时80％患者达到治疗反应，而安慰剂组仅31％（P〈0．001）；其他各项疗效指标治疗组也有明显的改善。常见不良反应为注射部位皮肤反应。结论：依那西普的安全性和耐受性好，能迅速减轻AS的症状和体征，控制AS患者的病情活动。
|
| 关 键 词： | 脊柱炎 强直性 肿瘤坏死因子d 依那西普 临床试验 |
Treatment of ankylosing spondylitis with recombinant human tumor necrosis factor-Fc fusion protein (etanercept): a multicenter,randomized,double-blind,placebo-controlled trial |
| |
| DENG Xiao-hu,HUANG Feng,ZHANG Ya-mei,YANG Chun-hua,GUO Jun-hua,LIANG Dong-feng,LI Sheng-guang,WANG Li-sha,ZHANG Jiang-lin.Treatment of ankylosing spondylitis with recombinant human tumor necrosis factor-Fc fusion protein (etanercept): a multicenter,randomized,double-blind,placebo-controlled trial[J].Academic Journal of Pla Postgraduate Medical School,2009,30(1):21-23. |
| |
| Authors: | DENG Xiao-hu HUANG Feng ZHANG Ya-mei YANG Chun-hua GUO Jun-hua LIANG Dong-feng LI Sheng-guang WANG Li-sha ZHANG Jiang-lin |
| |
| Institution: | Department of Rheumatology;Chinese PLA General Hospital;Beijing 100853;China |
| |
| Abstract: | Objective: To evaluate the efficacy and safety of recombinant human tumor necrosis factor receptor,Fc fusion protein,in treating ankylosing spondylitis(AS).Methods: This was a randomized,double-blind,placebo-controlled trial in the first 6 weeks and an open labeled trial in the next 6 weeks.52 patients of active AS were randomly assigned to receive twice weekly subcutaneous injections of etanercept(25mg) or placebo for 6 weeks.The primary endpoint was proportion of ASAS20 responders at week 6.The secondary ... |
| |
| Keywords: | spondylitis ankylosing tumor necrosis factor-alpha etanercept clinical trial |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
